BioCryst Pharmaceuticals, Inc. announced that the Institut national d'excellence en santé et services sociaux (INESSS) has issued a positive recommendation for PrORLADEYO® (berotralstat) to be reimbursed for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age and older in Quebec. Health Canada authorized ORLADEYO in June 2022 for the routine prevention of recurrent HAE attacks in patients 12 years and older. In February 2023, the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee issued a positive recommendation for ORLADEYO.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.11 USD | -1.13% | -0.65% | +2.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.00% | 1.26B | |
+16.13% | 122B | |
+19.65% | 113B | |
+17.29% | 26.49B | |
-23.84% | 19.4B | |
-18.86% | 16.24B | |
-19.28% | 15.4B | |
-45.95% | 15.15B | |
+63.81% | 14.93B | |
+1.94% | 13.52B |
- Stock Market
- Equities
- BCRX Stock
- News BioCryst Pharmaceuticals, Inc.
- INESSS Recommends Public Reimbursement for BioCryst?s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec